(HealthDay News) — The International Bladder Cancer Group (IBCG) has proposed a new definition of progression in nonmuscle invasive bladder cancer that is clinically useful for determining prognosis and comparing treatment options, according to research published in the January issue of The Journal of Urology.
Donald Lamm, MD, of the University of Arizona in Phoenix, and colleagues reviewed published clinical trials and meta-analyses to review current definitions and establish a new definition for progression in nonmuscle invasive bladder cancer.
The researchers found that progression in nonmuscle invasive bladder cancer is most commonly defined as an increase in stage from nonmuscle invasive to muscle invasive disease. However, this definition does not address other indicators of disease progression, such as lamina propria invasion and increase in grade.
The IBCG proposes that progression in nonmuscle invasive bladder cancer be defined as an increase in T stage from carcinoma in situ or Ta to T1 (lamina propria invasion), development of T2 or greater or lymph node (N+) disease or metastasis (M1), or an increase from low-grade to high-grade disease.
“Investigators should consider the use of this new definition to help standardize protocols and improve the reporting of progression,” the authors wrote.
Several authors disclosed financial ties to pharmaceutical companies, including Sanofi Pasteur, which contributed funding to the study.